ATE502628T1 - Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung - Google Patents

Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung

Info

Publication number
ATE502628T1
ATE502628T1 AT07724702T AT07724702T ATE502628T1 AT E502628 T1 ATE502628 T1 AT E502628T1 AT 07724702 T AT07724702 T AT 07724702T AT 07724702 T AT07724702 T AT 07724702T AT E502628 T1 ATE502628 T1 AT E502628T1
Authority
AT
Austria
Prior art keywords
spherical
glp
diseases
production
conditions associated
Prior art date
Application number
AT07724702T
Other languages
English (en)
Inventor
Peter Geigle
Christine Wallrapp
Eric Thoenes
Frank Thuermer
Original Assignee
Biocompatibles Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocompatibles Uk Ltd filed Critical Biocompatibles Uk Ltd
Application granted granted Critical
Publication of ATE502628T1 publication Critical patent/ATE502628T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
AT07724702T 2006-05-10 2007-04-27 Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung ATE502628T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06009678A EP1854455B1 (de) 2006-05-10 2006-05-10 GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
PCT/EP2007/003775 WO2007128443A2 (en) 2006-05-10 2007-04-27 Spherical or non-spherical microcapsules comprising glp-i peptides, their production and use

Publications (1)

Publication Number Publication Date
ATE502628T1 true ATE502628T1 (de) 2011-04-15

Family

ID=37773605

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06009678T ATE444741T1 (de) 2006-05-10 2006-05-10 Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
AT07724702T ATE502628T1 (de) 2006-05-10 2007-04-27 Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06009678T ATE444741T1 (de) 2006-05-10 2006-05-10 Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung

Country Status (13)

Country Link
US (2) US8790705B2 (de)
EP (3) EP1854455B1 (de)
JP (1) JP5209608B2 (de)
CN (1) CN101489539A (de)
AT (2) ATE444741T1 (de)
AU (1) AU2007247511B2 (de)
CA (1) CA2649902A1 (de)
DE (2) DE602006009631D1 (de)
DK (1) DK2015736T3 (de)
ES (1) ES2363810T3 (de)
PL (1) PL2015736T3 (de)
PT (1) PT2015736E (de)
WO (1) WO2007128443A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005017628D1 (de) 2005-09-22 2009-12-24 Biocompatibles Uk Ltd Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
DE602006009631D1 (de) * 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
EP1972349A1 (de) * 2007-03-21 2008-09-24 Biocompatibles UK Limited Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
US20100226976A1 (en) * 2007-07-11 2010-09-09 Marcelle Machluf Encapsulated mesenchymal stem cells and uses thereof
EP2163243A1 (de) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
EP2251028A1 (de) * 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Behandlung von Augenerkrankungen unter Verwendung eingekapselter Zellen, die einen antiangiogenetischen Faktor und/oder einen neuroprotektiven Faktor codieren und sekretieren
US20120020931A1 (en) 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
EP2616096A1 (de) * 2010-09-15 2013-07-24 Biocompatibles Uk Ltd. Behandlung von gefässerkrankungen unter verwendung eingekapselter zellen, die glp-1 kodieren und sezernieren, oder eines fragments oder einer variante davon
EP2665433B1 (de) 2011-01-19 2021-03-10 Fractyl Laboratories Inc. Vorrichtungen zur gewebebehandlung
CA2831184A1 (en) * 2011-03-29 2012-10-04 Myriam Lee Willy Bomans Method for encapsulated therapeutic products and uses thereof
US9388385B2 (en) * 2011-05-19 2016-07-12 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
KR101335176B1 (ko) * 2011-12-12 2013-11-29 테고사이언스 (주) 상처 치유용 드레싱재제
KR102245697B1 (ko) 2012-02-27 2021-04-28 프랙틸 래브러토리스 인코포레이티드 조직의 치료를 위한 열 절제 시스템，장치 및 방법
EP3711810B1 (de) 2012-04-19 2023-02-22 Fractyl Health, Inc. Gewebeexpansionssysteme
EP2879605A4 (de) 2012-07-30 2016-04-06 Fractyl Lab Inc Stromablationssysteme, vorrichtungen und verfahren zur behandlung von gewebe
EP2882362B1 (de) 2012-08-09 2024-01-03 Fractyl Health, Inc. Ablationssysteme, vorrichtungen und verfahren zur gewebebehandlung
EP2903626A4 (de) 2012-10-05 2016-10-19 Fractyl Lab Inc Verfahren, systeme und vorrichtungen zur durchführung mehrerer behandlungen eines patienten
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
EP3071286B1 (de) 2013-11-22 2024-01-03 Fractyl Health, Inc. Systeme zur erzeugung einer therapeutischen einschränkung im magen-darm-trakt
CN104805058A (zh) * 2014-01-23 2015-07-29 上海欧易生物医学科技有限公司 一种稳定表达外源性glp-1基因的人脐带源间充质干细胞株
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
EP3169260B1 (de) 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System zur behandlung von diabetes und zugehöriger erkrankungen und störungen
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
AU2016379403B2 (en) 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
CN111518770B (zh) * 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
CN111803617A (zh) * 2020-07-16 2020-10-23 卡杜兰(广州)生命基因工程科技有限公司 一种内载微囊的干细胞系统与制备方法
US20220389071A9 (en) * 2020-09-22 2022-12-08 Yang Wei Long-lasting glp1 analogue drug for type-2 diabetes
CN113493764B (zh) * 2021-07-27 2023-01-24 新乡医学院 一种体外诱导小鼠耳朵间充质干细胞分化为脂肪细胞的方法
WO2023028554A1 (en) * 2021-08-25 2023-03-02 Neuraly, Inc. Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
WO1992009698A1 (en) 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression of pace in host cells and methods of use thereof
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
EP0499990B1 (de) * 1991-02-19 1996-05-15 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung von cysteinfreien Peptiden
GB9311147D0 (en) 1993-05-28 1993-07-14 Long Ashton Research Station Regulation of plant growth
CZ297338B6 (cs) 1996-03-01 2006-11-15 Novo Nordisk A/S Peptid potlacující chut k jídlu, farmaceutický prostredek jej obsahující a jeho pouzití
CA2262647C (en) * 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US5830723A (en) 1996-08-13 1998-11-03 Regents Of The University Of Minnesota Method for immortalizing chicken cells
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
JP2001504105A (ja) 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１ペプチドの利用
WO1999035495A2 (en) 1998-01-12 1999-07-15 Betagene, Inc. Identification of substances that modify cellular secretory function
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
WO1999053064A2 (en) * 1998-04-13 1999-10-21 Modex Therapeutiques, S.A. Methods of delivering glp-1
DE19836960A1 (de) 1998-08-14 2000-02-17 Ulrich Zimmermann Verfahren zur Gewinnung hochgereinigter Alginate
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
DE19904785A1 (de) 1999-02-05 2000-08-10 Ulrich Zimmermann Verfahren zur Herstellung von stabilem Alginatmaterial
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
EP1634605A3 (de) 2000-03-08 2006-10-11 Novo Nordisk A/S Behandlung von Dyslipämie bei einem Patienten mit Typ 2 Diabetes
CA2434237C (en) 2000-12-07 2012-05-15 Eli Lilly And Company Glp-1 fusion proteins
US20020183253A1 (en) 2001-02-22 2002-12-05 Brazzell Romulus Kimbro Method of treating ocular neovascularization
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
EP1430115A1 (de) 2001-07-27 2004-06-23 Arhus Amt Immortalisierte stammzellen
EP2022505B1 (de) 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, Exendin-4, Peptid-Analoga und Verwendungen davon
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
EP1432430A4 (de) 2001-08-28 2006-05-10 Lilly Co Eli Vormischungen von glp-1 und basalinsulin
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
ATE352312T1 (de) * 2001-12-29 2007-02-15 Novo Nordisk As Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
CA2468700A1 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
JP4548335B2 (ja) 2003-03-07 2010-09-22 味の素株式会社 腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
EP1654004A2 (de) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthese und applikation von neuen strukturellen gut definierten verzweigten polymeren als konjugatmittel für peptide
CN100580087C (zh) 2003-10-10 2010-01-13 诺和诺德医疗保健公司 肽的缀合
KR20060109940A (ko) 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
CA2849552A1 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
MXPA06011425A (es) 2004-03-31 2007-03-12 Johnson & Johnson Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
KR20080050576A (ko) 2005-07-29 2008-06-09 앰프로틴 코포레이션 키메릭 치료제
DE602005017628D1 (de) 2005-09-22 2009-12-24 Biocompatibles Uk Ltd Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
DE602006009631D1 (de) * 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
EP1972349A1 (de) * 2007-03-21 2008-09-24 Biocompatibles UK Limited Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP1975176A1 (de) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung
EP2163243A1 (de) 2008-09-12 2010-03-17 Biocompatibles UK Limited Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern

Also Published As

Publication number Publication date
EP2015736B1 (de) 2011-03-23
DE602007013385D1 (de) 2011-05-05
EP2174655A1 (de) 2010-04-14
DE602006009631D1 (de) 2009-11-19
ATE444741T1 (de) 2009-10-15
EP1854455B1 (de) 2009-10-07
WO2007128443A3 (en) 2008-05-22
US8790705B2 (en) 2014-07-29
PT2015736E (pt) 2011-05-30
AU2007247511A1 (en) 2007-11-15
AU2007247511B2 (en) 2012-12-06
CN101489539A (zh) 2009-07-22
US20140105991A1 (en) 2014-04-17
JP2009536166A (ja) 2009-10-08
EP2015736A2 (de) 2009-01-21
ES2363810T3 (es) 2011-08-17
PL2015736T3 (pl) 2011-09-30
US20100068289A1 (en) 2010-03-18
JP5209608B2 (ja) 2013-06-12
EP1854455A1 (de) 2007-11-14
WO2007128443A2 (en) 2007-11-15
CA2649902A1 (en) 2007-11-15
DK2015736T3 (da) 2011-06-14

Similar Documents

Publication Publication Date Title
ATE502628T1 (de) Sphärische oder nichtsphärische mikrokapseln mit glp-1-peptiden, ihre herstellung und verwendung
WO2007133811A3 (en) Cd47 related compositions and methods for treating immunological diseases and disorders
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
WO2010049678A3 (en) Treatment of energy utilization diseases
WO2008070692A3 (en) Bicyclic compounds and use as antidiabetics
MX352265B (es) Neurotoxinas que exhiben actividad biologica acortada.
WO2005068498A3 (en) Human therapeutic cells secreting nerve growth factor
DE50312016D1 (de) Herstellung uretdiongruppenhaltiger Polyisocyanate mit Cycloalkylphosphinen als Katalysatoren
ATE521656T1 (de) Hydrophile, arylsiloxy-haltige makromonomere und polymere mit hohem brechungsindex sowie ophthalmische vorrichtungen mit solchen polymeren
WO2009129462A3 (en) Therapy target selection for psychiatric disorder therapy
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
Woelfle et al. Teneurins, TCAP, and latrophilins: roles in the etiology of mood disorders
DE602007011037D1 (de) Achsensteuerung bei der herstellung von torischen kontaktlinsen
ES2571991T3 (es) Procedimientos para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos
DE60337009D1 (de) Chimärisches protein
WO2004018633A3 (en) Abca13 nucleic acids and proteins, and uses thereof
WO2008061209A3 (en) G protein coupled receptors and uses thereof
ATE416192T1 (de) Protein, das sich an die zelloberflächenschichten bindet, und dessen verwendung
WO2008154516A3 (en) Btnl2 fusion protein for t-cell activity modulation
WO2008092445A3 (de) Verfahren zur modulation der immunantwort durch aktivierung oder inaktivierung des notch und/oder stat4 signalweges
WO2005101013A3 (en) Materials and methods for screening modulators of neural regneration
DE102005054091A1 (de) Schwefelvernetzte hydrierte Vinylpolybutadiene sowie deren Verwendung zur Herstellung von technischen Gummiartikeln mit guten Rückverformungsverhalten über einen breiten Temperaturbereich
ATE549400T1 (de) Polypeptid mit esterase aktivität sowie rekombinante esterase und verwendung davon
WO2006072601A3 (en) THERAPEUTIC USE OF GROWTH FACTORS, NsG29 AND NsG31
WO2005087806A3 (en) Cd38 splice variant and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2015736

Country of ref document: EP